hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06381635, orgStudyIdInfo id: FD-BUE-REC: IRB000124920, briefTitle: Effect of Aloe Vera Gel and Manuka Honey on Radiation Induced Oral Mucositis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2025-01-01, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, descriptionModule briefSummary: The goal of this \[ type of study: Clinical trial\] is to test effectiveness of Aloe Vera Gel and Manuka Honey in management of Radiation Induced Mucositis in head and neck cancer patients.The main question \[s\] \] is to \[ learn about, test, compare etc.\] it aims to answer are:1. Is Aloe Vera Gel and Manuka Honey effective in management of Radiation Induced Mucositis?2. Does Aloe Vera Gel and Manuka Honey affect the level of TGFβ1 and EGF in saliva of patients with radiation induced mucositis? participants will be asked to apply Aloe Vera Gel and Manuka Honey or saline three times daily during radiotherapy and 6 months after radiotherapy., conditionsModule conditions: Radiation Mucositis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Manuka honey mixed with aloe vera gel, outcomesModule primaryOutcomes measure: Change from World Health Organization Oral Toxicity Scale Grading of Oral Mucositis, secondaryOutcomes measure: the level of salivary transforming growth factor beta 1, secondaryOutcomes measure: the level of salivary Epidermal Growth factor (EGF), eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: ain shams University, status: RECRUITING, city: Cairo, zip: 11565, country: Egypt, contacts name: hani wlliam, MD, role: CONTACT, phone: +20 0001000093885, email: ethicscommittee.fdasurec@gmail.com, geoPoint lat: 30.06263, lon: 31.24967, locations facility: Fatma E.Sayed, status: RECRUITING, city: Cairo, country: Egypt, contacts name: Fatma E. Hassanein, PHD, role: CONTACT, phone: +201000093885, email: fatmahassanein@dent.asu.edu.eg, contacts name: Asma Abou Bakr, role: CONTACT, email: Asmaa.Aboubakr@bue.edu.eg, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06381622, orgStudyIdInfo id: CTA no: 2023-510028-63-00, briefTitle: Combining Lidocaine and Ropivacaine for an Infraclavicular Brachial Plexus Nerve Block, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-18, primaryCompletionDateStruct date: 2024-08-03, completionDateStruct date: 2024-09-03, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Nordsjaellands Hospital, class: OTHER, descriptionModule briefSummary: The aim of the study is to investigate how the combination of ropivacaine (a slow onset, long duration local anesthetic) with lidocaine (a rapid onset, shorter duration local anesthetic) affects the onset and duration of a lateral infraclavicular plexus brachialis (LIC) block in patients undergoing non-acute hand surgery., conditionsModule conditions: Nerve Block, conditions: Anesthesia, Local, conditions: Forearm Fracture, conditions: Surgery, conditions: Brachial Plexus Block, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 78, type: ESTIMATED, armsInterventionsModule interventions name: Ropivacaine 0.5% Injectable Solution, interventions name: Lidocaine epinephrine, interventions name: Ropivacaine 0.75% Injectable Solution, outcomesModule primaryOutcomes measure: Total time to breakthrough pain, secondaryOutcomes measure: The onset of sensory block, secondaryOutcomes measure: Total duration of sensory blockade, secondaryOutcomes measure: Total duration of motor blockade, secondaryOutcomes measure: Degree of motor blockade, otherOutcomes measure: Pain intensity at pain breakthrough, otherOutcomes measure: Duration of maximum pain intensity after the blockade has ended, otherOutcomes measure: Occurence of adverse events (AE) and serious adverse events (SAE), otherOutcomes measure: Failed blockade, otherOutcomes measure: The patient's experience of the treatment (patient satisfaction), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Nordsjælland Hospital, status: RECRUITING, city: Hillerød, zip: 3400, country: Denmark, contacts name: Lars H Lundstrøm, PhD, role: CONTACT, phone: 48296512, phoneExt: 45, email: lars.hyldborg.lundstroem.02@regionh.dk, contacts name: Christian Rothe, PhD, role: CONTACT, phone: 48297459, phoneExt: 45, email: christian.rothe@regionh.dk, geoPoint lat: 55.92791, lon: 12.30081, hasResults: False
protocolSection identificationModule nctId: NCT06381596, orgStudyIdInfo id: 2023-1715, secondaryIdInfos id: A536000, type: OTHER, domain: UW- Madison, secondaryIdInfos id: SMPH/OPHTHAL&VIS SCI/GEN, type: OTHER, domain: UW- Madison, secondaryIdInfos id: Protocol Version 3/6/2024, type: OTHER, domain: UW- Madison, briefTitle: Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration, acronym: FPF in AMD, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: University of Wisconsin, Madison, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to learn if the areas of stressed cells in the retina correlate to areas of disease identified in standard imaging and whether the images are helpful to identify potential areas of concern before symptoms or disease occurs. The main question it aims to answer is:* to evaluate patterns of increased autofluorescence FPF in the setting of geographic atrophyParticipants will undergo FPF imaging using the OcuMet Beacon system., conditionsModule conditions: Geographic Atrophy, conditions: Age-Related Macular Degeneration, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: OcuMet Beacon, outcomesModule primaryOutcomes measure: Limits of agreement between the fundus autofluorescence (FAF) area of GA images taken with the Heidelberg Spectralis to the flavoprotein fluorescence (FPF) area of GA with images taken with the OcuMet Beacon, secondaryOutcomes measure: Compare the cross-sectional associations between FPF intensity (average pixel intensity over a 5.5 mm-diameter region centered at the macula) to FAF area at the time of measurement, secondaryOutcomes measure: Compare the cross-sectional associations between best corrected visual acuity (BCVA - using Early Treatment Diabetic Retinopathy Study, greater number of letters read correctly equals better vision) to FAF area at the time of measurement, eligibilityModule sex: ALL, minimumAge: 50 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Ophthalmology and Visual Sciences, city: Madison, state: Wisconsin, zip: 53705, country: United States, contacts name: Amy Remm, role: CONTACT, phone: 608-262-3377, email: amy.remm@wisc.edu, contacts name: Mihai Mititelu, MD, MPH, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.07305, lon: -89.40123, hasResults: False
protocolSection identificationModule nctId: NCT06381583, orgStudyIdInfo id: 23228/EMERALD, briefTitle: A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma, acronym: EMERALD, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-04-15, primaryCompletionDateStruct date: 2026-06-18, completionDateStruct date: 2026-06-18, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: City of Hope Medical Center, class: OTHER, descriptionModule briefSummary: This study aims to develop a highly sensitive, specific, and cost-effective blood assay for the early detection of esophageal adenocarcinoma and its precursor lesions, using advanced machine learning and state-of-the-art biological analyses., conditionsModule conditions: Esophagus Cancer, conditions: Esophageal Cancer Stage, conditions: Esophageal Cancer, conditions: Esophageal Neoplasms, conditions: Esophagus Adenocarcinoma, conditions: Esophagus, Barrett, conditions: Barrett Esophagus, conditions: Barrett Adenocarcinoma, conditions: Barrett Epithelium, conditions: Barretts Esophagus With Dysplasia, conditions: Barrett's Esophagus Without Dysplasia, conditions: Barretts Esophagus With High Grade Dysplasia, conditions: Barretts Esophagus With Low Grade Dysplasia, conditions: Barrett Esophagus, Long-Segment, conditions: Barrett's Esophagus With Dysplasia, Unspecified, conditions: Barrett's Esophagus With Esophagitis, conditions: Gastroesophageal Reflux, conditions: Reflux Disease, conditions: Esophageal Adenocarcinoma, conditions: Esophageal Dysplasia, conditions: Esophageal Neoplasms Malignant, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia), outcomesModule primaryOutcomes measure: Sensitivity, secondaryOutcomes measure: Specificity, secondaryOutcomes measure: Proportion of correct predictions (true positives and true negatives) among the total number of cases (i.e., accuracy), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: City of Hope Medical Center, status: RECRUITING, city: Duarte, state: California, zip: 91016, country: United States, contacts name: Ajay Goel, PhD, role: CONTACT, phone: 626-218-3452, email: AJGOEL@COH.ORG, contacts name: Ajay Goel, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Alessandro Mannucci, MD, role: SUB_INVESTIGATOR, geoPoint lat: 34.13945, lon: -117.97729, hasResults: False
protocolSection identificationModule nctId: NCT06381570, orgStudyIdInfo id: VICTORY/OZM-138, briefTitle: Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas, acronym: VICTORY, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-21, primaryCompletionDateStruct date: 2026-03-21, completionDateStruct date: 2029-03-21, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Daniel Morgenstern, class: OTHER, collaborators name: The Hospital for Sick Children, descriptionModule briefSummary: This is a Pilot, multicenter, open-label study of patients less than or equal to 25 years, with recurrent or progressive LGG harboring a CRAF or BRAF alteration, including BRAF V600 mutations and KIAA1549: BRAF fusions. Patients with BRAF or CRAF alterations will be identified through molecular assays as routinely performed at Clinical Laboratory Improvement Amendments (CLIA) of 1988 or other similarly certified laboratories.The study will be conducted in two sequential phases:Phase A: A Feasibility (combination dose finding) phase, followed by Phase B: An Efficacy phase. The maximum tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D) of the combination as determined in Phase A would be the dose used in Phase B. The patients on Phase A who were below the MTD/RP2D would be eligible for intra-patient dose escalation to MTD/RP2D subject to criteria outlined later, conditionsModule conditions: Low-grade Glioma, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 57, type: ESTIMATED, armsInterventionsModule interventions name: Tovorafenib, outcomesModule primaryOutcomes measure: MTD/RP2D, primaryOutcomes measure: Safety and Tolerability, primaryOutcomes measure: Overall response rate, secondaryOutcomes measure: Pharmacokinetics (Cmax vinblastine and tovorafenib), secondaryOutcomes measure: Pharmacokinetics (AUC of vinblastine and tovorafenib), secondaryOutcomes measure: Progression free survival, secondaryOutcomes measure: Duration of response, secondaryOutcomes measure: Clinical Benefit rate, eligibilityModule sex: ALL, minimumAge: 0 Weeks, maximumAge: 25 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: The Hospital for Sick Children, status: RECRUITING, city: Toronto, state: Ontario, zip: M5G 1X8, country: Canada, contacts name: Nirav Thacker, role: CONTACT, phone: 6137377600, phoneExt: 6525, email: nthacker@cheo.on.ca, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False
protocolSection identificationModule nctId: NCT06381557, orgStudyIdInfo id: YRPG-PMS-ZYJN-RCT-2022-01, briefTitle: Cancer-related Fatigue in Patients With Breast Cancer Treatment With Zhengyuan Capsules, acronym: CRF, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2027-03-01, completionDateStruct date: 2027-03-01, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Qiang Fu, class: OTHER, collaborators name: Yangtze River Pharmaceutical Group Co., Ltd., descriptionModule briefSummary: Traditional Chinese medicine（TCM） has achieved some meaningful results in improving the symptoms and quality of life of cancer patients, but many research results need to be further verified by clinical trials with larger samples and better design.This study aims to investigate effectiveness and safety of Zhengyuan Capsules for cancer-related fatigue in patients with breast cancer., conditionsModule conditions: Cancer-related Fatigue, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 240, type: ESTIMATED, armsInterventionsModule interventions name: Zhengyuan Capsules, interventions name: Placebo contains 5%-10% Zhengyuan Capsule total mixed powder, outcomesModule primaryOutcomes measure: Fatigue degree with the Brief Fatigue Inventory（BFI）, secondaryOutcomes measure: Fatigue degree the Revised Piper Fatigue Scale（PFS⁃R）, secondaryOutcomes measure: Fatigue degree with the MD Anderson Symptom Inventory（MDASI）, secondaryOutcomes measure: Change of patients' functional status with Karnofsky performance status (KPS), secondaryOutcomes measure: Quality of Life Questionnaire-Breast Cancer Module 23（QLQ-BR23）, otherOutcomes measure: Adverse reaction rates, including the damage of liver and renal functions that reflected by increased alanine aminotransferase, aspartate aminotransferase and creatinine urea nitrogen respectively, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06381544, orgStudyIdInfo id: fbu_nurs_elmali_002, briefTitle: The Effect of Aromatherapy Use in Nursing Skills Training, statusModule overallStatus: COMPLETED, startDateStruct date: 2024-02-12, primaryCompletionDateStruct date: 2024-02-19, completionDateStruct date: 2024-03-06, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Fenerbahce University, class: OTHER, descriptionModule briefSummary: Nursing education is an education in which theory and practice are intertwined and requires the development of both cognitive and motor skills of students. The laboratory environment is a bridge between classroom learning and clinical practice. In order for students to transform the target behavior into a skill, it takes place in the laboratory on inanimate models under the supervision of the instructor. It has been assumed that there is a strong relationship between learning and anxiety; while a moderate level of anxiety is necessary for learning, a high level of anxiety causes a decrease in learning.Many studies have reported that students experience anxiety before their first clinical/practice experience. During skills training, it is observed that students are stressed, their hands are shaking, and they do not feel comfortable, especially before practices involving invasive interventions. This is a factor that makes learning skills training difficult. Therefore, it is important for the student to be comfortable, self-confident, and mentally open to learning during skill training. New applications and different techniques for skill training are important in this sense. It is reported that aromatherapy application has positive effects on reducing anxiety and increasing concentration.RESEARCH HYPOTHESES:H0: Aromatherapy has no effect on students' anxiety and learning levels during skill training.H1: Aromatherapy reduces the anxiety experienced by students during skills training.H2: Aromatherapy has a positive effect on students' learning nursing skills., conditionsModule conditions: Nursing Students, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 69, type: ACTUAL, armsInterventionsModule interventions name: Aromatherapy application, outcomesModule primaryOutcomes measure: Difference between skill learning of students in the aromatherapy group and the control group, secondaryOutcomes measure: Difference between anxiety levels of students in the aromatherapy group and the control group, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fenerbahce University, city: Istanbul, state: Atasehir, zip: 34758, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, locations facility: Fenerbahce University, city: Ataşehir, state: Istanbul, zip: 34758, country: Turkey, geoPoint lat: 40.9833, lon: 29.1167, hasResults: False
protocolSection identificationModule nctId: NCT06381531, orgStudyIdInfo id: 4410, briefTitle: Tracing Brain Tumors Through Deep Time, acronym: TRACE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-10, primaryCompletionDateStruct date: 2027-06-10, completionDateStruct date: 2027-06-10, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Tata Memorial Centre, class: OTHER, collaborators name: Indian Statistical Institute, Kolkata, descriptionModule briefSummary: Brain tumors involve different age groups with a wide range of tumor types involving different anatomical compartments of the brain. The evolution of the brain in vertebrates, including the most recent homo species (including humans), has occurred through increasing structural complexity in more evolved species. In the retrospective study, we will investigate the location of the tumors and different structural aspects of skull anatomy in patients with brain tumors. The information will be compared with the anatomical evolution of the brain and skull in vertebrates to look for possible associations, which can provide insights into evolutionary biology., conditionsModule conditions: Brain Tumor, conditions: Oncology, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 10000, type: ESTIMATED, armsInterventionsModule interventions name: Imaging with CT and MRI, outcomesModule primaryOutcomes measure: Age-based density maps of brain tumor location, secondaryOutcomes measure: Anthropometric analysis of skulls, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tata Memorial Hospital, city: Mumbai, state: Maharashtra, zip: 400012, country: India, contacts name: Dr Archya Dasgupta, MD, role: CONTACT, geoPoint lat: 19.07283, lon: 72.88261, hasResults: False
protocolSection identificationModule nctId: NCT06381518, orgStudyIdInfo id: Z2023165, briefTitle: Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease, acronym: SHUFFLE, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-03-12, primaryCompletionDateStruct date: 2025-05-01, completionDateStruct date: 2025-05-01, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Zuyderland Medisch Centrum, class: OTHER, descriptionModule briefSummary: The aim of this study is to evaluate the IFX exposure (AUC), effectiveness, presence of ADAbs and treatment burden before and after switching from IV to SC IFX maintenance treatment in a real-world cohort of IBD patients with quiescent disease on IFX monotherapy and combination therapy of IFX and an immunomodulator.Methods: this is a prospective, single centre, open-label cohort study, conducted in Zuyderland Medical Centre in which 36 adult IBD patients in remission on stable IV IFX therapy are switched to SC CT-P13 of which 18 patients use an immunomodulator in addition to IFX (cohort 2). After the switch to SC CT-P13, patients are followed for 24 weeks.The study is subdivided into two phases: the IV IFX treatment phase before switching and the SC CT-P13 treatment phase after the switch. After enrolment, the subject receives a final dose of IV IFX according to their own maintenance schedule. Primary endpoints are the Area under the concentration-time curve (AUC) at steady state (1) before and after the switch to SC CT-P13 and (2) with or without concomitant immunomodulator during SC therapy. AUCs will be estimated using pharmacokinetic modelling in MwPharm. Besides IFX trough level, treatment related time expenditure, quality-of-life and patient satisfaction will be assessed before and after the switch., conditionsModule conditions: IBD, conditions: Infliximab, conditions: Crohn Disease, conditions: Ulcerative Colitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, interventionModelDescription: This is a prospective, single centre, open-label cohort study, conducted in Zuyderland Medical Centre in which adult IBD patients in remission on stable IV IFX therapy are switched to SC CT-P13 and is designed to compare the pharmacokinetics of SC CT-P13 to IV IFX and relate this to the pharmacodynamics., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: Switch to SC CT-P13., outcomesModule primaryOutcomes measure: Area under the curve (AUC) at steady state, secondaryOutcomes measure: Quality of life score, secondaryOutcomes measure: Patient satisfaction, secondaryOutcomes measure: Time expenditure, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zuyderland Medical Centre, city: Sittard, country: Netherlands, geoPoint lat: 50.99833, lon: 5.86944, hasResults: False